Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q4 2012 | Q4 2011 |
|---|---|---|
| Revenue | $1.09M | $42.00K |
| Net Income | -$13.51M | $81.98M |
| EPS Diluted | -$0.51 | $2.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
